GlobeNewswire by notified

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

Share

Company announcement – No. 39 / 2023

Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

Copenhagen, Denmark, November 16, 2023 Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 26,637 divided into 26,637 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs.

Employee warrant programs are part of Zealand Pharma’s incentive scheme, and each warrant gives the owner the right to subscribe for one newly issued Zealand Pharma share at a prespecified price, the exercise price, in specific predefined time periods before expiration. For a more detailed description of Zealand Pharma’s warrant programs, see the company’s Articles of Association, which are available on the website: www.zealandpharma.com.

The exercise price was DKK 127.00 per share for 9,119 of the new shares, DKK 224.40 per share for 12,518 of the new shares and DKK 220.00 per share for 5,000 of new shares. The total proceeds to Zealand from the capital increase amount to DKK 5,067,152.2.

The new shares give rights to dividend and other rights from the time of the warrant holder's exercise notice. Each new share carries one vote at Zealand Pharma’s general meetings. Zealand Pharma has only one class of shares.

The new shares will be listed on Nasdaq Copenhagen after registration of the capital increase with the Danish Business Authority. Following registration of the new shares, the share capital of Zealand Pharma will be nominal DKK 58,704,075 divided into 58,704,075 shares with a nominal value of DKK 1 each.

A full copy of the amended Articles of Association can be found at https://www.zealandpharma.com once registered with the Danish Business Authority.

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development and partnerships with a number of blue-chip pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.

Contacts:

Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: ank@zealandpharma.com
Adam Lange
Investor Relations Officer
Zealand Pharma
Email: akl@zealandpharma.com
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Havila Kystruten AS: Fourth quarter 2023 accounts28.2.2024 22:24:49 CET | Press release

Summary The company has completed its first quarter with full operation of all four ships. Revenue in the fourth quarter was MNOK 249. Due to late clarification on the delivery of the last two ships, the revenue side is somewhat lower than if the pre-sale had started earlier. The last quarter of 2023 ended with an average fleet occupancy of 60%, an average cabin rate (ACR) of NOK 3,100 and a utilization rate of 1.8 per cabin. Occupancy and average price per cabin are higher than the fourth quarter of 2022, but are somewhat lower than the third quarter due to lower demand in the autumn and winter months. EBITDA was negative by MNOK 33.2 in the fourth quarter and MNOK 179 for the full year. Operating costs amounted to MNOK 283 in the fourth quarter and are mainly ordinary operating costs for operating four ships. Some of the operating costs are related to the number of passengers, while the largest cost items are not significantly affected by occupancy. MNOK 18 relates to extraordinary m

Havila Kystruten AS: Regnskap for fjerde kvartal 202328.2.2024 22:24:49 CET | Pressemelding

Sammendrag Selskapet har gjennomført sitt første kvartal med full drift av alle fire skip. Inntektene utgjorde i fjerde kvartal MNOK 249. Som følge av sen avklaring på levering av de to siste skipene, er inntektssiden noe lavere enn om forhåndssalget hadde startet før. Siste kvartal i 2023 endte med et gjennomsnittlig belegg for flåten på 60%, en gjennomsnittlig lugarrate (ACR) på NOK 3 100 og en utnyttelsesgrad på 1,8 per lugar. Belegg og gjennomsnittspris per lugar er høyere enn fjerde kvartal 2022, men er noe lavere enn tredje kvartal som følge av lavere etterspørsel i høst- og vintermånedene. EBITDA var negativ med MNOK 33,2 i fjerde kvartal og MNOK 179 for hele året. Driftskostnadene utgjør MNOK 283 i fjerde kvartal og er hovedsakelig ordinære driftskostnader for drift av fire skip. Deler av driftskostnadene er knyttet til antall passasjerer, mens de største kostnadspostene ikke er vesentlig påvirket av belegg. MNOK 18 gjelder ekstraordinære kostnader til markedsføring for å sikre

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update28.2.2024 22:15:25 CET | Press release

- Petosemtamab in 1L HNSCC in combination with pembrolizumab initial interim clinical data planned for 2Q24; preparing for a potential phase 3 trial - Petosemtamab in 2L+ HNSCC phase 3 trial planned to initiate mid-2024; interim clinical data planned for 2H24 - Petosemtamab in 2L CRC: cohort planned to initiate in 2024 - Zeno in NRG1+ cancer: Sufficient clinical data expected in 1H24 to support potential BLA submissions - Based on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2027 UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced financial results for the fourth quarter and full year and provided a business update. “2024 is poised to be a transformational year for Merus.

Magnus Nicolin proposed as new Chairman of Hexatronic Group28.2.2024 21:15:00 CET | Press release

Press release February 28, 2024 Gothenburg, Sweden Magnus Nicolin proposed as new Chairman of Hexatronic Group The Nomination Committee of Hexatronic Group AB (publ) has informed the company that it intends to propose Magnus Nicolin for election as Chairman of the Board of Hexatronic, at the Annual General Meeting that will be held on May 7, 2024. Anders Persson has informed the Nomination Committee that he intends to step down from his position as Chairman if the Nomination Committee finds a suitable candidate for the position. The Nomination Committee has now announced that Magnus Nicolin is available as Chairman and that Anders Persson has informed the Nomination Committee that he therefore will not be available for re-election at the Annual General Meeting. The Nomination Committee therefore intends to propose Magnus Nicolin as new Chairman of the Board of Hexatronic. Until the date of the Annual General Meeting, Anders Persson will continue to lead the Board’s work. Magnus Nicolin

Magnus Nicolin föreslås som ny styrelseordförande i Hexatronic Group28.2.2024 21:15:00 CET | Pressemelding

Pressmeddelande 28 februari, 2024 Göteborg Sverige Magnus Nicolin föreslås som ny styrelseordförande i Hexatronic Group Valberedningen i Hexatronic Group AB (publ) har informerat bolaget att de har för avsikt att föreslå att Magnus Nicolin ska väljas till ny styrelseordförande vid årsstämman den 7 maj 2024. Anders Persson har informerat valberedningen, att förutsatt att valberedningen hittar en ny kandidat till posten som styrelseordförande, ställer han sin plats till förfogande. Valberedningen har nu meddelat att Magnus Nicolin står till förfogande som ny styrelseordförande och att Anders Persson har meddelat att han därmed inte är tillgänglig för omval vid årsstämman. Valberedningen avser därför att föreslå Magnus Nicolin som ny styrelseordförande för Hexatronic. Anders Persson kommer att fortsätta att leda styrelsens arbete fram till och med årsstämman. Magnus Nicolin har omfattande internationell erfarenhet och är idag styrelseordförande i Munters Group AB (publ) samt styrelseledam

HiddenA line styled icon from Orion Icon Library.Eye